RxDoctor Payments Data

Michael Collins, MD

Ophthalmology · Fort Myers, FLNPI 1801882394

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 34.9% of the total. Reporting peaked in 2024 at $4,453 and has fallen 73.5% since, to $1,178 in 2025.

$9,911in general payments, 2019–2025

Across 123 payments — averaging $80.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$3K
  • Sight Sciences, Inc.$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson Surgical Vision, Inc.$579
  • Rxsight Inc$377
  • Ocular Therapeutix, Inc.$293
  • plus $826 from 10 others
$108,000in research payments, 2019–2025

Across 11 payments — averaging $9818.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rxsight Inc$108K

What the payments were for

  • Consulting fees$2,80028%
  • Speaking & faculty fees$1,86919%
  • Food & beverage$5,24253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,911 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$572,990
Medicare patients
655
Services billed
3,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketorolac Tromethamine27$468
Brimonidine Tartrate13$189
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$117

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Fort Myers

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →